Arteriolesclerosis obliterans
Conditions
Interventions
Control group:Cilostazol tablets
Integrated group:Danggui Sini Decoction integrated with cilostazol tablets
Sponsors
Xingcheng Hospital of Tradioanl Chinese Medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: ? Meet the diagnostic standards of traditional Chinese medicine and Western medicine mentioned above; ? Age>40 years old; ? Living independently, moving freely, with normal mental and cognitive functions; ? Complete clinical data; ? Voluntarily participate in this study and sign an informed consent form; ? 0.5<ABI = 0.90.
Exclusion criteria
Exclusion criteria: ? Hemorrhagic patients (such as hemophilia, capillary fragility, intracranial hemorrhage, gastrointestinal bleeding, urinary tract bleeding, hemoptysis, vitreous hemorrhage, etc.); ? Patients with poor compliance, failure to receive treatment as required, or self medicating with other treatment measures; ? Patients with organic liver, kidney, and lung lesions such as liver injury, renal insufficiency, and respiratory failure; ? Patients with severe cardiovascular and cerebrovascular diseases, as well as patients with congestive heart failure, who are accompanied by or have experienced acute coronary syndrome, cerebral hemorrhage, cerebral thrombosis, etc.; ? Pregnant or lactating women, and patients in preparation for pregnancy and childbirth; ? Patients with autoimmune, infectious diseases and lower limb ulcers; ? Urgent surgical reconstruction of arterial access; ?Patients with a history of allergies to the drugs used in the experiment.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| ABI;Toe temprerature ;Neutrophil/lymphocyte ratio, NLR; | — |
Secondary
| Measure | Time frame |
|---|---|
| Blood pressure, blood sugar, blood lipids, blood routine, urine routine, liver function, kidney function, electrocardiogram; | — |
Countries
China
Contacts
Public ContactZheng Chengjun
Xingcheng Hospital of Traditional Chinese Medicine
Outcome results
None listed